APG Asset Management N.V. Has $25.46 Million Holdings in ResMed Inc. (NYSE:RMD)

APG Asset Management N.V. increased its holdings in ResMed Inc. (NYSE:RMD) by 42.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,551 shares of the medical equipment provider’s stock after buying an additional 42,332 shares during the period. APG Asset Management N.V. owned 0.10% of ResMed worth $25,460,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in ResMed by 24.9% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 177,083 shares of the medical equipment provider’s stock valued at $35,068,000 after acquiring an additional 35,273 shares in the last quarter. Mediolanum International Funds Ltd acquired a new position in ResMed in the first quarter valued at about $2,246,000. Janney Montgomery Scott LLC lifted its position in ResMed by 5.3% during the first quarter. Janney Montgomery Scott LLC now owns 81,313 shares of the medical equipment provider’s stock worth $16,102,000 after purchasing an additional 4,075 shares during the period. Los Angeles Capital Management LLC grew its stake in ResMed by 3,599.0% during the first quarter. Los Angeles Capital Management LLC now owns 499,031 shares of the medical equipment provider’s stock worth $98,823,000 after buying an additional 485,540 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in ResMed in the 4th quarter valued at about $7,535,000. 54.98% of the stock is currently owned by institutional investors.

Insider Activity at ResMed

In other ResMed news, insider Justin Leong sold 48,000 shares of ResMed stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the transaction, the insider now directly owns 18,741 shares of the company’s stock, valued at approximately $4,068,108.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Justin Leong sold 48,000 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the completion of the transaction, the insider now directly owns 18,741 shares in the company, valued at $4,068,108.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kaushik Ghoshal sold 5,000 shares of ResMed stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total value of $1,262,800.00. Following the completion of the transaction, the insider now directly owns 21,788 shares in the company, valued at $5,502,777.28. The disclosure for this sale can be found here. Insiders sold 102,931 shares of company stock worth $22,644,807 over the last three months. Company insiders own 1.21% of the company’s stock.

ResMed Stock Performance

Shares of RMD stock opened at $239.00 on Friday. The firm has a market capitalization of $35.12 billion, a price-to-earnings ratio of 36.71, a PEG ratio of 2.46 and a beta of 0.69. The company has a current ratio of 2.59, a quick ratio of 1.69 and a debt-to-equity ratio of 0.14. The business’s 50-day moving average price is $230.00 and its 200-day moving average price is $210.84. ResMed Inc. has a 12 month low of $132.24 and a 12 month high of $255.18.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 EPS for the quarter, topping the consensus estimate of $2.03 by $0.05. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.22 billion. During the same period last year, the company earned $1.60 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. Equities research analysts forecast that ResMed Inc. will post 8.92 EPS for the current year.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 19th. Investors of record on Thursday, August 15th were paid a $0.53 dividend. This is a boost from ResMed’s previous quarterly dividend of $0.48. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $2.12 annualized dividend and a dividend yield of 0.89%. ResMed’s payout ratio is currently 32.57%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on RMD shares. Baird R W raised shares of ResMed to a “strong-buy” rating in a report on Tuesday. StockNews.com cut ResMed from a “buy” rating to a “hold” rating in a research note on Friday, August 30th. Citigroup lowered ResMed from a “buy” rating to a “neutral” rating in a research note on Monday, June 24th. Wolfe Research restated an “underperform” rating and set a $180.00 price objective on shares of ResMed in a research report on Wednesday, September 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research report on Wednesday, September 18th. One analyst has rated the stock with a sell rating, six have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $212.25.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.